Journal of Vaccines & Vaccination

Global presence of your research at 12^th Global summit on Immunology and Cell Biology, scheduled during April 06-07, 2020 in Manila, Philippines.

Elsa Catherine^* Department of Immunology, Federal University of Uberlandia, Brazil
^*Correspondence: Elsa Catherine, Department of Immunology, Federal University of Uberlandia, Brazil, Email:

Received: 01-Dec-2020 Published: 22-Dec-2020

Importance and Scope

Conference series LLC LTD gives a good opportunity and invites global participants of Immunology and Cell Biology Researchers to the Immunology Congress 2020 in Manila, Philippines this year 2020. The event will mainly focus on the Modern exploration of techniques in Immunology and Cell Biology research and provide deep knowledge. It is a Global platform that combines different domains, will stimulate the exchange of ideas and enable participants to grasp the modern exploration techniques and ideas in different areas of Immunology and cell biology research. The event includes prompt keynote presentations, Oral talks, Poster presentations Young Research Forum and Exhibitions.

With members from around the world targeted on learning concerning Immunology and Cell Biology and its advances; this is often your best chance to succeed in the most important assemblage of participants from the Immunology and Cell Biology community. Conduct shows, distribute info, meet with current and potential scientists, create a splash with new discoveries within the advanced techniques, and receive name recognition at this 2-day event. World-renowned speakers, the foremost recent techniques, developments are hallmarks of this conference.

Market analysis

Global Immunology Market to 2022

Immune-mediated inflammatory diseases are a very common set of chronic disorders that affect 5-7% of western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a highly genericized class of systemic small-moleculebased agents, are used in the first-line treatment of these diseases. These are supplemented in many cases by shorterterm glucocorticoid therapy, another class of highly genericized systemic agents.

Scope

• Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth, from $61.5 billion in 2015 to $74.2 billion in 2022, at a compound annual growth rate of 2.71%.

• What factors are driving market growth?

• How can the factors limiting growth be overcome?

• There is a very large pharmaceutical pipeline for immunology, consisting of 1,838 products in active development. However, the commercial performance of the products in the late-stage pipeline is expected to be moderate.

• What gaps in the market are being addressed by the most promising of these late-stage pipeline products?

• How does the composition of the pipeline compare with that of the existing market?

• Several key commercially successful products, including Humira (adalimumab) and Remicade, are due to lose patent protection in the forecast period.

• How will this affect their revenues in this period?

• How are their manufacturers, AbbVie and Johnson & Johnson, responding to this?

• The key players in the market, all of which are among the top 20 pharmaceutical companies, are expected to maintain their market lead throughout the forecast period.

• What is driving this continued market dominance?

• Who will the new market players be?

• International Conference on Robotics, AI & ML